Nanoscope Technologies received a $1.5M NIH SBIR grant to develop gene-agnostic glaucoma therapy utilizing Engineered Mechanosensitive Channels (EMCs). EMCs can autonomously regulate pressure, offering a novel approach to treating Glaucoma.
Researchers at Nanoscope developed functional retinal organoids with photoreceptors and RPE cell layers, a key model for age-related macular degeneration. They also created an organoid model that is highly reproducible for high-throughput drug screening.
Nanoscope Technologies is featuring groundbreaking research on optical gene delivery and functional characterization platform technologies for treating retinal diseases. The company's lead product, vMCO-010, delivers light-sensitive Multi-Characteristics Opsin into retinal cells to restore vision in patients with degeneration.
Nanoscope Technologies has developed a novel, non-viral gene delivery approach using low-power near-infrared lasers to target the retina. The method sensitizes cells to ambient light, improving visual response and offering a unique therapy option for dry-AMD patients.
Nanoscope Technologies has received multiple NIH grants to further develop its gene delivery and optogenetics platforms for treating and monitoring retinal degenerative diseases, such as Age-related macular degeneration. The company aims to improve visual acuity in patients with these conditions through targeted retinal stimulation.
The team aims to develop a modular and scalable interface system that can modulate and monitor large-scale activities in the nervous system, with potential applications for pain management, epilepsy, and neurological disorders. They plan to advance bioluminescence imaging instead of fluorescence to enable long-term cortical imaging wit...
Nanoscope Technologies has been awarded a National Institutes of Health (NIH) Audacious Goal Initiative grant to develop ultrafast laser-based gene delivery technology for vision restoration. The company aims to re-sensitize photo-degenerated retinal areas with a highly photosensitive Multi-Characteristics Opsin (MCO) using an infrared...
Researchers have developed a new viral vector-based delivery system for retinal cells, aiming to treat visual impairments caused by age-related macular degeneration (AMD). The system uses highly photosensitive opsins to stimulate retinal cells and restore vision.